Abstract: Methods and compositions are provided for the treatment of staphylococcal infections.

Abstract: Compositions and methods for the treatment and diagnosis of lipopolysaccharide-related conditions and coagulant-related disease are provided. Compositions include polypeptides which are identical or homologous to a certain cationic protein (CAP18) obtained from mammalian granulocytes, particularly including a reactive nitrogen inhibiting peptide (RNIP) fragment found at the carboxy-terminus of CAP18. Polypeptides are capable of binding to LPS and inhibiting LPS-mediated activation of macrophage, as well as interfering with the clotting cascade to inhibit coagulation in conditions such as disseminated intravascular coagulation. Compositions comprising the polypeptides in a suitable pharmaceutical carrier are also provided.

Abstract: Multifunctional proteins having M-CSF activity and at least one other bioactivity not found together in a single naturally occuring molecule are described. These multifunctional M-CSF proteins can be produced by the expression of fused genes which are also described. These multifunctional M-CSF proteins have increased therapeutic potential.

Abstract: A method is disclosed for assaying for inhibitors of a 24 kDa cytoplasmic protease associated with apoptosis. The protease has a defined amino acid composition, activity against the elastase-like substrate MAAVP, and induces DNA fragmentation associated with apoptosis in isolated U937 cell target nuclei.

Abstract: The present invention relates to novel DNA alkylating agents and the prodrugs of these agents which are useful as antitumor agents and DNA labelling agents. The compounds are hydroxy dihydrobenzindole oligopeptides and prodrugs thereof wherein the monomeric constituents are derived from monocyclic or bicyclic heterocyclic aromatic residues.

Abstract: A method for controlling the overgrowth of hyperproliferating cells in the presence of non-proliferating cells by exposing the hyperproliferating cells to a toxin conjugate that has a binding region that binds to an internalizable element of the hyperproliferating cell and a toxic moiety bound thereto is provided. The toxin conjugate may be a monoclonal antibody to transferrin receptor. Such toxin conjugates will have use in controlling hyperproliferative diseases of the integument and the eye.

Abstract: Compositions and methods for the treatment and diagnosis of lipopolysaccharide-related conditions and coagulant-related disease are provided. Compositions include polypeptides which are identical or homologous to a certain cationic protein (CAP18) obtained from mammalian granulocytes, particularly including a reactive nitrogen inhibiting peptide (RNIP) fragment found at the carboxyl-terminus of CAP18. Polypeptides are capable of binding to LPS and inhibiting LPS-mediated activation of macrophage, as well as interfering with the clotting cascade to inhibit coagulation in conditions such as disseminated intravascular coagulation. Compositions comprising the polypeptides in a suitable pharmaceutical carrier are also provided.

Abstract: An apoptosis-associated protease having a relative mass of 24 kilodaltons and a defined amino acid composition is disclosed, together with a method for its purification from a cytoplasmic extract of mammalian cells treated with an apoptosis-inducing agent, such as tumor necrosis factor-.alpha. or UV irradiation, that comprises affinity chromatography with the serine protease inhibitor DK120 followed by heparin-sepharose chromatography. The protease has activity against the elastase-like substrate MAAPV and is capable of inducing apoptosis in isolated U937 cell target nuclei.

Abstract: Multifunctional proteins having M-CSF activity and at least one other bioactivity not found together in a single naturally occuring molecule are described. These multifunctional M-CSF proteins can be produced by the expression of fused genes which are also described. These multifunctional M-CSF proteins have increased therapeutic potential.

Abstract: A novel human hepatokine, referred to hereinafter as HPX, has been isolated and purified from human fetal hepatocytes. HPX has a molecular weight of approximately 15 kD, a pI of about 6, and has been found to promote hepatocyte growth activity in vitro and in vivo.

Abstract: A stable, continuous human cell line or progeny thereof is produced that is resistant to 6-thioguanine and ouabain, secretes less than 40 ng/ml of endogenous IgM antibodies, and grows with a doubling time of about 18 hours. The cell line, which preferably is adapted to serum-free medium, may be used as a fusion partner with an antibody-producing cell line so as to generate antibodies. In addition, it may be electroporated with a vector containing a gene of interest to produce a transformed cell line which generates a protein encoded by the gene, such as an IgG or IgM antibody.

Abstract: Human T-T hybridomas are made by fusing an azaserine-hypoxanthine (AH) sensitive T leukemia cell line, preferably the AH-sensitive mutant of the Jurkat leukemia line identified as J3R7, with normal T cells and culturing the fusion product in a selective AH medium. Stable, interleukin-2 (IL-2)-producing human T-T hybridomas were made by this process.

Abstract: A 6-thioguanine-resistant subvariant of the EBV-transformed human lymphoblastoid B cell line WI-L2 is described. The subvariant line, designated LTR228, fuses efficiently with human cells. Human.times.human hybridomas derived from LTR228 that produce monoclonal antibodies against tetanus toxin and blood group A are exemplified.

Abstract: A human monoclonal antibody that directly agglutinates type A human red blood cells is described. The exemplified antibody is an IgM and is produced by hybrid cells lines S-H22 and HHA1. The antibody is useful as an ABO typing reagent.

Abstract: A method for controlling weight by suppressing the normal metabolism of adipose tissue is disclosed. Administration of tumor necrosis factor (TNF) or a pharmaceutical composition containing it results in suppression of anabolism of adipose cells.

Abstract: Anti-Pseudomonas antibodies which bind to exotoxin A from P. aeruginosa are prepared from hybrid cell lines. The antibodies may be of any isotype. These antibodies may be used to treat infections caused by P. aeruginosa.

Abstract: A 6-thioguanine-resistant subvariant of the EBV-transformed human lymphoblastoid B cell line WI-L2 is described. The subvariant line, designated LTR228, fuses efficiently with human cells. Human.times.human hybridomas derived from LTR228 that produce monoclonal antibodies against tetanus toxin and blood group A are exemplified.

Abstract: Serotype-specific murine anti-Pseudomonas monoclonal antibodies which bind to determinants of the cell wall lipopolysaccharides of P. aeruginosa are prepared from hybrid cell lines. The antibodies may be of any isotype. These antibodies may be used to treat infections caused by P. aeruginosa.

Abstract: Serotype-specific human anti-Pseudomonas monoclonal antibodies which bind to determinants of the cell wall lipopolysaccharides of P. aeruginosa are prepared from hybrid cell lines. The antibodies may be of any isotype. These antibodies may be used to treat infections caused by P. aeruginosa.